Board of Directors and Scientific Advisory Board

Bharath Takulapalli, PhD

Founder & CEO

Bharath is inventor of multiple foundational life science technologies at the interface of nanotechnology, systems biology and ML/AI, to extract 100x more information from systems biology than currently possible. He conceived Sensor-integrated Proteome On Chip (SPOC) technology to bridge a big gap in proteomics space, to democratize high-throughput functional protein screening. SPOC is the first and only technology that enables production of 1000s of full-length folded proteins on 1.5 sq-cm biosensor chips, to simultaneously screen for qualitative, quantitative, and kinetic information on protein bindings/interactions in a single assay, at once. Bharath is also the inventor of FENT solid-state nanopore technology for 1000x faster DNA sequencing at 1/10th cost, being developed by iNanoBio Inc. Bharath’s vision is to achieve 90% disease preemption, which is to detect and intervene in pre-disease phases, to cure before full disease onset.

Mukilan Mohan, MS MBA

Co-Founder & COO

Mukilan Mohan is an entrepreneur and technology leader with a passion to improve human health through early diagnosis of diseases. He is the co-founder of SPOC Proteomics and INanoBio. At SPOC Proteomics, his responsibilities include product & general  management, operations and finance. He works with Bharath on business strategy and corporate development. Previously, he led product management and system design functions for order to cash systems at TD-Ameritrade’s investor education division. He has a Master’s degree in Electrical Engineering from the Ira A. Fulton School of Engineering and an MBA from the W.P. Carey School of Business both at Arizona State University in Tempe.

Dr. Lydia Gushgari

Director of Clinical Research & Chief of Staff

Dr. Lydia Gushgari has 10 years’ experience in immunology, including virology, infectious diseases, vaccine development, melanoma, clinical laboratory diagnostic immunology, and autoimmunity. Lydia completed her Doctoral studies at Arizona State University, studying plant-produced vaccines and attenuated viral vaccine vectors for HIV. Her postdoctoral work was completed at University of Arizona College of Medicine, where she studied T cell responses to melanoma and antigen presentation. Prior to starting at SPOC Proteomics, she served as Acting Director of a CLIA-certified laboratory, performing high-complexity immunology assays. Dr. Gushgari is the Director of Clinical Research and Chief of Staff at SPOC Proteomics where she assists with building strategic partnerships, project management, and clinical research for diagnostics using the SPOC platform.

Chair: Dr. George Church - Professor of Genetics

Harvard Medical School

Dr. George Church is professor of Genetics at Harvard Medical School and director of Personal Genome Project. His 1984 Harvard PhD included the first methods for direct genome sequencing and molecular multiplexing, which helped initiate the Human Genome Project. In addition to innovations that contributed to nearly all next generation sequencing methods, Dr. Church is a principle inventor of protein nanopore sequencing. He has founded close to a dozen companies in the areas of Genomic Medicine, Gene Therapy and Synthetic Biology, such as Editas, Gen9, WarpDrive, Joule, Knome to name a few. Dr. Church has also pioneered new privacy, biosafety , environmental & biosecurity policies.

Dr. Chenming Hu – Professor of EECS

University of California, Berkeley

Dr. Chenming Hu, Professor Emeritus of EECS at UC Berkeley, is the visionary inventor of the FinFET or 3D transistor architecture. He is a world’s foremost authority on CMOS device physics, modeling and manufacturing. To address the limits of Moore’s law scaling in CMOS transistors, Dr. Hu conceived the tri-gate FinFET design that enables further scaling and integration in the third dimension by stacking-up transistors vertically. Intel began commercializing the 3D transistor based chips in 2011, with most others following soon. Dr. Hu served as Chief Technology Officer of TSMC from 2001 to 2004. He has authored four books and 900 research papers, and has been granted over 100 US patents.

Dr. Joshua LaBaer – Director, Center for Personalized Medicine

ASU Biodesign Institute

Dr. Joshua LaBaer is the Director of Virginia Piper center for personalized diagnostics at the Biodesign Institute ASU, home to DNASU plasmid repository and the Sequencing Core. He is a medical oncologist, cancer researcher and nation’s leading proteomics expert. Dr. LaBaer was previously director of the Harvard Institute of Proteomics (HIP), he is founding member and serving president of US HUPO (Human Proteome Organization). He is the principal inventor of NAPPA protein microarray technologies. Dr. LaBaer is a former member of the National Cancer Institute (NCI) Board of Scientific Advisors, and currently serves as chair of NCI’s Early Detection Research Network.

Dr. Abhay Sanan – President, Center for Neurosciences

Center for Neurosciences, Tucson

Dr. Abhay Sanan is a Neurosurgeon with more than 24 years of experience in broad areas of neurosciences. He understands how technology drives outcomes and is currently leading a clinical partnership with INanoBio for development of diagnostic technologies for early CNS disease detection, with an initial focus on brain tumors. He is a board certified neurosurgeon who has held numerous management positions. In addition to his role at Center for Neurosciences Tucson, he serves as Director of Neurosciences at Tucson Medical Center and as Clinical Assistant Professor at the University of Arizona, Division of Neurosurgery. Dr. Sanan and his research have received numerous awards throughout his career.

Jean Pierre Millon, MBA


JP Millon currently serves on the board of CVS Health that combines CVS Pharmacy, Caremark, Minute Clinic and CVS Specialty. He is the former President and Chief Executive Officer of PCS Health Systems Inc. He previously served on the boards of Caremark Rx and Advance PCS. Prior to that, he served in multiple leadership positions at Eli Lilly, including as President and General Manager of Lilly Japan. He has over 25 years of functional management, financial management and strategic planning experience. He serves on the boards of multiple other companies, on the CEO advisory board of a private equity firm and on the board of St Joseph Hospital Phoenix.